A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)
- DOI
- 10.1016/j.leukres.2025.107717
- Published
- 2025-08
- Container
- Leukemia Research
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.leukres.2025.107717,
title = {A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)},
author = {Brian A. Jonas and Samantha C. Fisch and Peter T. Curtin and Gary J. Schiller and Deepa Jeyakumar and Dimitrios Tzachanis and Rafael Bejar and Lihong Qi and Matthew J. Wieduwilt and Joseph M. Tuscano and Lloyd Damon and Aaron C. Logan},
year = {2025},
journal = {Leukemia Research},
doi = {10.1016/j.leukres.2025.107717},
url = {https://doi.org/10.1016/j.leukres.2025.107717}
}RIS
TY - JOUR TI - A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503) AU - Brian A. Jonas AU - Samantha C. Fisch AU - Peter T. Curtin AU - Gary J. Schiller AU - Deepa Jeyakumar AU - Dimitrios Tzachanis AU - Rafael Bejar AU - Lihong Qi AU - Matthew J. Wieduwilt AU - Joseph M. Tuscano AU - Lloyd Damon AU - Aaron C. Logan PY - 2025 JO - Leukemia Research DO - 10.1016/j.leukres.2025.107717 UR - https://doi.org/10.1016/j.leukres.2025.107717 ER -
APA
Jonas, B. A., Fisch, S. C., Curtin, P. T., Schiller, G. J., Jeyakumar, D., Tzachanis, D., Bejar, R., Qi, L., Wieduwilt, M. J., Tuscano, J. M., Damon, L., & Logan, A. C. (2025). A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leukemia Research. https://doi.org/10.1016/j.leukres.2025.107717
Source records
- crossref · retrieved 2026-09-26T20:28:10.120Z